This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
IMAAVY™ (nipocalimab-aahu)
Medical Information
IMAAVY – Use in Pediatric Patients with Warm Autoimmune Hemolytic Anemia
Last Updated: 08/25/2026
SUMMARY
- The company cannot recommend any practices, procedures, or usage of IMAAVY that deviate from the approved labeling.
- Use of IMAAVY in pediatric patients 12 years of age and older with warm autoimmune hemolytic anemia (wAIHA) currently or previously treated with corticosteroids is supported by evidence from an adequate and well-controlled trial in adults with additional pharmacokinetic data in pediatric patients who are 12 years of age and older.1
- Steady-state serum concentrations of IMAAVY are predicted to be similar between adults and pediatric patients 12 to <18 years of age with wAIHA.1
Literature Search
A literature search of MEDLINE®
References
| 1 | IMAAVY (nipocalimab) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc; https://www.jnjlabels.com/package-insert/product-monograph/prescribing-information/IMAAVY-pi.pdf |
Would you like to clear and leave your conversation? Message history will be lost.